Search Results
Dec 23, 2025, 07:04 ET Nizars neuer Anfang
Er war gerade einmal fünf Jahre alt und spielte mit seinen Geschwistern, als eine Kugel in den Kopf bekam. Die Verletzung zerschmetterte einen Teil seines Schädels und prägte seine Kindheit
More news about: Education Cannot Wait
Dec 22, 2025, 08:46 ET Aqualung Therapeutics Receives FDA Clearance for Phase 2a Lung Fibrosis Study
than 20 peer-reviewed publications validating the preclinical utility of ALT-100 mAb. "Our dramatic disease-attenuating effects of the ALT-100 mAb in preclinical models of lung fibrosis combined with the preliminary evidence of ALT-100 mAb's ability to dampen innate immunity activation and disease severity
More news about: Aqualung Therapeutics
Dec 19, 2025, 09:00 ET Tolmar Announces Expanded Indication for Rubraca® (rucaparib) First and Only PARP Inhibitor to Outperform Docetaxel in a Head-to-Head Phase 3 Trial
(10%).Most common select laboratory abnormalities of patients with BRCA-mutated mCRPC treated with RUBRACA in TRITON3 (≥ 25%, Grade 1-4) were increased ALT (68%), decreased neutrophils (67%), decreased phosphate (64%), decreased hemoglobin (60%), increased AST (59%), increased creatinine (56%), increased
More news about: TOLMAR
Dec 17, 2025, 18:49 ET U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)
pruritus (24%), and nausea (21%). The most common Grade 3 or 4 laboratory abnormalities (≥2%) were decreased albumin (8%), decreased sodium (7%), increased ALT (7%), decreased potassium (5%), decreased hemoglobin (3.8%), increased AST (3.8%), increased GGT (2.6%), and increased magnesium (2.6%).Serious
More news about: Johnson & Johnson
Dec 17, 2025, 07:00 ET Reins celebrates helping contractors administer more than $25 million in alternative equity throughout 2025
businesses through alternative equity solutions, announces a milestone year of growth and customer momentum, highlighted by more than $25 million in alt equity shared with employees across its client base.
More news about: Reins
Dec 17, 2025, 06:45 ET PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
treatment of MIBC: increased glucose, decreased hemoglobin, increased aspartate aminotransferase (AST), rash, increased alanine aminotransferase (ALT), fatigue, pruritus, increased creatinine, decreased sodium, decreased lymphocytes, peripheral neuropathy, increased potassium, alopecia, dysgeusia,
More news about: Astellas Pharma Inc.
Dec 17, 2025, 06:00 ET BMI Offers Accessibility on Demand™
WCAG-ready outputSearchable PDF conversion, enabling improved access and readabilityAlt text generation, including contextual and custom optionsAudit-ready validation, with scoring aligned to WCAG 2.1
More news about: BMI Imaging Systems, Inc.
Dec 16, 2025, 15:00 ET Bandsintown Drops 2025 High Notes: Fans, Festivals, and Genres That Ruled the Year in Live Music
subgenres like phonk, and latin trap, that brought new energy to the sound.Shoegaze jumped 37%, reflecting a growing interest in alt and atmospheric sounds.Rock reclaimed the #1 spot in fan engagement, with Metal and Alternative coming in at #2
More news about: Bandsintown
Dec 15, 2025, 13:03 ET ALT5 Investor Alert: Hagens Berman Scrutinizing ALT5 Sigma (ALTS) Over Potential Disclosure Violations
commenced an investigation into ALT5 Sigma Corporation (NASDAQ: ALTS) following a series of new disclosures that point to a potential crisis of governance and regulatory non-compliance, which led to the stock cratering nearly 80%. The firm urges investors in ALT5 who suffered significant losses
More news about: Hagens Berman Sobol Shapiro LLP
Dec 12, 2025, 20:25 ET U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*
fulminant hepatitis, acute liver failure, and deaths.In AMPLITUDE, Grade 3-4 ALT or AST increases (at least 5x ULN) were reported in 1.9% and 1.3% of patients, respectively.In MAGNITUDE Cohort 1, Grade 3-4 ALT or AST increases (at least 5x ULN) were reported in 1.8% and 0.9% of patients respectively.The
More news about: Johnson & Johnson
Dec 12, 2025, 14:23 ET ALT5 Investor Alert: Hagens Berman Scrutinizing ALT5 Sigma (ALTS) Over Potential Disclosure Violations
commenced an investigation into ALT5 Sigma Corporation (NASDAQ: ALTS) following a series of new disclosures that point to a potential crisis of governance and regulatory non-compliance, which led to the stock cratering nearly 80%. The firm urges investors in ALT5 who suffered significant losses
More news about: Hagens Berman Sobol Shapiro LLP
Dec 12, 2025, 11:45 ET Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer
increases in alanine aminotransferase (ALT) (2 to 6%) and aspartate aminotransferase (AST) (2 to 3%) were reported in patients receiving Verzenio. Across three clinical trials in 3559 patients (monarchE, MONARCH 2, MONARCH 3), the median time to onset of Grade ≥3 ALT increases ranged from 57 to 87
More news about: Eli Lilly and Company
Dec 11, 2025, 23:15 ET ALT5 INVESTIGATION ALERT: Investigation Launched into ALT5 Sigma Corporation, Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm - ALTS
financial statements of [ALT5 Sigma] and omissions of material information by certain members of management and personnel of [ALT5 Sigma]."Then, on October 22, 2025, ALT5 Sigma revealed that "[o]n October 16, 2025, Peter Tassiopoulos was suspended by the Board of Directors of Alt5 Sigma . . . and removed
More news about: Robbins Geller Rudman & Dowd LLP
Dec 11, 2025, 09:30 ET ALT5 Investor Alert: Hagens Berman Investigates ALT5 Sigma (ALTS) Over Auditor Resignation and Potentially False Financials
www.youtube.com/watch?v=G4qAPizCnxAALT5 Sigma (ALTS) Investigation: The investigation focuses on the propriety of ALT5's repeated assurances that its financial reports are prepared in conformity with generally accepted accounting
More news about: Hagens Berman Sobol Shapiro LLP
Dec 11, 2025, 08:30 ET Major League Table Tennis Partners with IC360 and ALT Sports Data To Support Launch of Regulated Wagering for the 2025-26 Season
ic360.io.About ALT Sports Data:ALT Sports Data is bringing the next wave of consumers to sports betting. By empowering alternative sports leagues to participate in legal live sports betting, ALT Sports Data enables their partners to activate,
More news about: Major League Table Tennis
Dec 10, 2025, 14:16 ET Menarini Group apresenta os dados da fase 2 da combinação de elacestranto (ORSERDU®) em pacientes com câncer de mama metastático (mBC) ER+, HER2- no San Antonio Breast Cancer Symposium 2025 (SABCS)
aumento de colesterol (30%), aumento de AST (29%), aumento de triglicérides (27%), fadiga (26%), diminuição de hemoglobina (26%), vômito (19%), aumento de ALT (17%), diminuição de sódio (16%), aumento de creatinina (16%), diminuição de apetite(15%), diarreia(13%), cefaleia (12%), constipação (12%), dor abdominal
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 10, 2025, 14:02 ET Menarini Group presenta datos de combinación de fase 2 de Elacestrant (ORSERDU®) en pacientes con cáncer de mama metastásico (CMM) ER+, con HER2 en el Simposio de Cáncer de Mama 2025 en San Antonio
colesterol (30 %), aumento de AST (29 %), aumento de triglicéridos (27 %), fatiga (26 %), disminución de la hemoglobina (26 %), vómitos (19 %), aumento de ALT (17 %), disminución de sodio (16 %), aumento de creatinina (16 %), disminución del apetito (15 %), diarrea (13 %), cefalea (12 %), estreñimiento (12 %),
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 09, 2025, 21:21 ET PR Newswire Dukung Era AI, Sambut Masa Depan Penelusuran dan Penemuan Informasi Berbasiskan AI
Ya, konten multimedia sangat penting. Meski LLM tidak "melihat" gambar seperti manusia, AI menganalisis teks yang terkait dengan gambar—seperti alt text, keterangan foto, dan nama berkas—untuk memahami konteks.Selain itu, media visual meningkatkan interaksi audiens manusia. Aktivitas
More news about: PR Newswire
Dec 09, 2025, 14:24 ET Menarini Group 於 2025 年聖安東尼奧乳癌研討會公佈 Elacestrant (ORSERDU®) 針對 ER+、HER2- 轉移性乳癌 (mBC) 患者的第 2 期聯合治療數據
治療的患者出現致命的不良反應，包括心臟驟停、敗血性休克、憩室炎和原因不明的情況（各一例）。ORSERDU 最常見的不良反應 (> 10%)，包括實驗室異常，是肌肉骨骼疼痛 (41%)、噁心 (35%)、膽固醇升高 (30%)、AST 增加 (29%)、甘油三酯增加 (27%)、疲勞 (26%)、血紅蛋白下降 (26%)、嘔吐 (19%)、ALT 增高 (17%)、鈉降低 (16%)、肌酸增加 (16%)、食慾下降 (15%)、腹瀉 (13%)、頭痛 (12%)、便秘 (12%)、腹痛 (11%)、潮熱 (11%) 和消化不良 (10%)。藥物交互反應同時服用 CYP3A4 誘導劑和/或抑制劑：切勿同時服用強效或中效
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 09, 2025, 11:38 ET El Grupo Menarini presenta datos de la combinación de fase 2 de Elacestrant (ORSERDU®) en cáncer de mama
colesterol (30 %), aumento de AST (29 %), aumento de triglicéridos (27 %), fatiga (26 %), disminución de la hemoglobina (26 %), vómitos (19 %), aumento de ALT (17 %), disminución del sodio (16 %), aumento de la creatinina (16 %), disminución del apetito (15 %), diarrea (13 %), cefalea (12 %), estreñimiento
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 09, 2025, 09:49 ET 메나리니 그룹, 2025 샌안토니오 유방암 심포지엄에서 엘라세스트란트(ORSERDU)®의 ER+, HER2- 전이성 유방암(mBC) 환자 대상 2상 병용 요법 데이터 발표
ORSERDU에서 10% 초과로 보고된 가장 흔한 이상 반응(실험실 검사 수치 이상 포함)은 근골격계 통증(41%), 오심(35%), 콜레스테롤 증가(30%), AST 증가(29%), 중성지방 증가(27%), 피로(26%), 헤모글로빈 감소(26%), 구토(19%), ALT 증가(17%), 나트륨 감소(16%), 크레아티닌 증가(16%), 식욕 감소(15%), 설사(13%), 두통(12%), 변비(12%), 복통(11%), 안면홍조(11%), 소화불량(10%) 등으로 나타났다.약물 상호작용CYP3A4
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 09, 2025, 07:44 ET Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
failure. Elevated aspartate aminotransferase (AST) occurred in 34% of patients, with Grade 3 or 4 elevations in 1.2%. Elevated alanine aminotransferase (ALT) occurred in 28% of patients, with Grade 3 or 4 elevations in 1.8%. Elevated total bilirubin occurred in 6% of patients with Grade 3 or 4 elevations
More news about: Johnson & Johnson
Dec 09, 2025, 07:30 ET Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL
AST increased (17; 1.6), pneumonia (16; 14), bruising (16; -), potassium decreased (13; 1.6), sodium decreased (13; -), lipase increased (12; 4.4), ALT increased (11; 1.6), potassium increased (11; 0.8), alkaline phosphatase increased (11; -). Grade 4 laboratory abnormalities in >5% of patients included
More news about: Eli Lilly and Company
Dec 08, 2025, 14:47 ET Menarini Group präsentiert Daten zur Phase-2-Kombination von Elacestrant (ORSERDU®) bei Patientinnen mit ER+, HER2- metastasiertem Brustkrebs (mBC) auf dem San Antonio Breast Cancer Symposium 2025
erhöhtes Cholesterin (30 %), erhöhtes AST (29 %), erhöhte Triglyceride (27 %), Müdigkeit (26 %), vermindertes Hämoglobin (26 %), Erbrechen (19 %), erhöhte ALT (17 %), vermindertes Natrium (16 %), erhöhtes Kreatinin (16 %), verminderter Appetit (15 %), Durchfall (13 %), Kopfschmerzen (12 %), Verstopfung (12
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 08, 2025, 13:41 ET Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium
increased cholesterol (30%), increased AST (29%), increased triglycerides (27%), fatigue (26%), decreased hemoglobin (26%), vomiting (19%), increased ALT (17%), decreased sodium (16%), increased creatinine (16%), decreased appetite(15%), diarrhea(13%), headache (12%), constipation (12%), abdominal pain
More news about: Menarini Industrie Farmaceutiche Riunite